Solid Tumor: Clinical Trials

45 trials for Solid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

45 unknown. 45 Phase 2, 30 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 245Unknown 45
Phase 130Unknown 30

Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor

Trials (filtered) newest first · largest first

All 45 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
ZG005 Powder for Injection, Donafenib Tosilate Tablets - Solid Tumor
Phase 1 / Phase 2UnknownSuzhou Zelgen Biopharmaceuticals Co.,Ltd1302024-05-102024-06-14
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
QLS31905, Nab paclitaxel, Gemcitabine - Solid Tumor
Phase 1 / Phase 2UnknownQilu Pharmaceutical Co., Ltd.1152023-10-012023-09-18
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
ZG2001 Tosilate Tablets - Solid Tumor, KRAS Mutation-Related Tumors
Phase 1 / Phase 2UnknownSuzhou Zelgen Biopharmaceuticals Co.,Ltd1102023-08-102024-03-06
BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors
BPB-101 - Solid Tumor
Phase 1 / Phase 2UnknownBetta Pharmaceuticals Co., Ltd.3882023-05-162023-06-06
Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors
Pemigatinib - Solid Tumor, FGF Receptor Gene Mutation
Phase 2UnknownTianjin Medical University Second Hospital202023-05-012023-09-01
A Study of RD14-01 in Patients With Advanced Solid Tumors
RD14-01 - Solid Tumor
Phase 1 / Phase 2Unknown920th Hospital of Joint Logistics Support Force of People's Liberation Army of China122023-02-082023-03-01
ALG.APV-527 First-in-human Study
ALG.APV-527 - Solid Tumor
Phase 1 / Phase 2UnknownAptevo Therapeutics562022-12-232023-07-07
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation
HLX208 - Solid Tumor
Phase 2UnknownShanghai Henlius Biotech302022-10-202022-09-06
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
RX-af01, Mixed bacteria, High dose RX-af01 - Solid Tumor, Immune Checkpoint Inhibitor
Phase 1 / Phase 2UnknownSun Yat-sen University602022-09-152024-01-23
Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer
Dalpiciclib - Solid Tumor
Phase 2UnknownHebei Medical University Fourth Hospital302022-09-102022-08-23
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
IMM01, Tislelizumab - Solid Tumor, Classic Hodgkin Lymphoma
Phase 1 / Phase 2UnknownImmuneOnco Biopharmaceuticals (Shanghai) Inc.3092022-05-172023-04-27
An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors
Pyrotinib Maleate, standard regimen - Solid Tumor
Phase 2UnknownZhongshan Hospital Xiamen University602022-03-042022-03-10
Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors
HS-10365 - Solid Tumor
Phase 1 / Phase 2UnknownJiangsu Hansoh Pharmaceutical Co., Ltd.3062021-11-092023-06-01
A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
GT90001+KN046, GT90001/KN046 - Solid Tumor
Phase 1 / Phase 2UnknownSuzhou Kintor Pharmaceutical Inc,2162021-11-022024-02-09
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 - Carcinoma, Solid Tumor
Phase 2UnknownSecond Affiliated Hospital of Soochow University552021-11-012021-11-10
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
CURATE.AI, Nivolumab, Pembrolizumab - Solid Tumor
Phase 1 / Phase 2UnknownNational University Hospital, Singapore102021-08-192023-03-03
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
T3011 - Solid Tumor, Hepatocellular Carcinoma
Phase 1 / Phase 2UnknownImmVira Pharma Co. Ltd422021-08-102024-03-04
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
EU101 - Solid Tumor, Renal Cell Cancer Metastatic
Phase 1 / Phase 2UnknownEutilex1102021-05-312024-03-15
An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma
Manganese Chloride, Radiotherapy, Chemo-immunotherapy - Solid Tumor, Lymphoma
Phase 1 / Phase 2UnknownChinese PLA General Hospital102021-05-062021-05-05
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
SY-5007 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2UnknownShouyao Holdings (Beijing) Co. LTD1842021-04-232023-04-12

Showing 20 of 45. Sign in to see all of them.

Narrower conditions

Neoplasms (5)  ·  Stomach Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Carcinoma (3)  ·  Lymphoma (3)  ·  Neoplasm Metastasis (3)  ·  Carcinoma, Renal Cell (2)  ·  Melanoma (2)  ·  Ovarian Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Acrocephalosyndactylia (1)  ·  Anus Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Medullary (1)  ·  Carcinoma, Merkel Cell (1)

Broader conditions

Neoplasms (15)  ·  Neoplasms by Histologic Type (11)  ·  Neoplasms by Site (11)  ·  Digestive System Diseases (7)  ·  Digestive System Neoplasms (7)  ·  Gastrointestinal Diseases (6)  ·  Gastrointestinal Neoplasms (6)  ·  Neoplasms, Glandular and Epithelial (6)  ·  Bronchial Neoplasms (5)  ·  Carcinoma, Bronchogenic (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Lung Diseases (5)  ·  Lung Neoplasms (5)  ·  Respiratory Tract Diseases (5)  ·  Respiratory Tract Neoplasms (5)

Interventions

pembrolizumab (4)  ·  Injections (3)  ·  Radiotherapy (3)  ·  Capecitabine (2)  ·  Interleukin-2 (2)  ·  Nivolumab (2)  ·  Paclitaxel (2)  ·  SHR-1701 (2)  ·  apatinib (2)  ·  atezolizumab (2)  ·  niraparib (2)  ·  AZD8186 (1)  ·  Alpelisib (1)  ·  Antigens, CD1d (1)  ·  Cannabidiol (1)

Sponsors

Chinese PLA General Hospital (4)  ·  National University Hospital, Singapore (2)  ·  Seoul National University Bundang Hospital (2)  ·  Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2)  ·  Tianjin Medical University Second Hospital (2)  ·  920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1)  ·  Altum Pharmaceuticals INC (1)  ·  Aptevo Therapeutics (1)  ·  Asclepius Technology Company Group (Suzhou) Co., Ltd. (1)  ·  Beijing Hospital (1)  ·  Beijing InnoCare Pharma Tech Co., Ltd. (1)  ·  Betta Pharmaceuticals Co., Ltd. (1)  ·  Bio-Thera Solutions (1)  ·  Chungbuk National University Hospital (1)  ·  ENB Therapeutics, Inc (1)

Countries

China (25)  ·  United States (8)  ·  South Korea (4)  ·  Singapore (2)  ·  Australia (1)  ·  Belgium (1)  ·  Sweden (1)  ·  Taiwan (1)

Top investigators

Jason Wu (2)  ·  Raghav Sundar (2)  ·  Angela Ogden, MD (1)  ·  Anish Thomas, MD (1)  ·  Atsushi Osada (1)  ·  Baorui Baorui Liu, Doctor (1)  ·  Hadas Lemberg, PhD (1)  ·  HaiTao Wang, Ph.D (1)  ·  Haitao Wang (1)  ·  Hui Wang, MD (1)  ·  Jiayi Chen, MD (1)  ·  Jin Li, PhD (1)  ·  Keun-Wook Lee, MD, PhD (1)  ·  Keun-Wook Lee, MD. & Ph.D (1)  ·  Ki Hyeong Lee, M.D. (1)

Results publications

PMID 24523121, PMID 26984449, PMID 27053773, PMID 30089632, PMID 30094065, PMID 31771394, PMID 32108102, PMID 33634869, PMID 34713106, PMID 35920783, PMID 37036671, PMID 37056765, PMID 38172595, PMID 38954010, PMID 39489747, PMID 39948624, PMID 42337043, PMID 42542997